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Abstract 
Background: The transmissible forms of Plasmodium parasites result from a process of sporogony that takes place 
inside their obligatory mosquito vector and culminates in the formation of mammalian-infective parasite forms. 
Ivermectin is a member of the avermectin family of endectocides, which has been proposed to inhibit malaria trans-
mission due its insecticidal effect. However, it remains unclear whether ivermectin also exerts a direct action on the 
parasite’s blood and transmission stages.
Methods: We employed a rodent model of infection to assess the impact of ivermectin treatment on P. berghei 
asexual and sexual blood forms in vivo. We then made use of a newly established luminescence-based methodology 
to evaluate the activity of ivermectin and other avermectins against the sporogonic stages of P. berghei parasites in 
vitro independent of their role on mosquito physiology.
Results: Our results show that whereas ivermectin does not affect the parasite’s parasitemia, gametocytemia or 
exflagellation in the mammalian host, several members of the avermectin family of compounds exert a strong inhibi-
tory effect on the generation and development of P. berghei oocysts.
Conclusions: Our results shed light on the action of avermectins against Plasmodium transmission stages and high-
light the potential of these compounds to help prevent the spread of malaria.
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Background
Malaria is a parasitic disease caused by Plasmodium 
parasites that are transmitted to their mammalian hosts 
by the bites of infected female Anopheles mosquitoes. 
In 2017, an estimated 435,000 deaths were attributed to 
malaria, 80% of which occurred in the regions of Africa 
and India and 61% of which in children under the age 
of 5. Although the number of malaria cases decreased 
from 2010, progress appears to have stalled, and a small 
increase in the global number of cases was actually 
observed in recent years [1].
Plasmodium sporozoites are injected by infected 
Anopheles mosquitoes into a mammalian host, homing 
to the liver, where they replicate into thousands of blood-
infective merozoites [2].While most merozoites cyclically 
invade red blood cells, leading to disease [3], some differ-
entiate into female and male gametocytes, which can be 
uptaken by mosquitoes [4]. Inside the mosquito midgut, 
gametocytes differentiate into female and male gametes 
that fuse forming zygotes [5]. In rodent P. berghei para-
sites, zygotes transform into ookinetes within 18–24  h, 
penetrating the mosquito’s midgut wall, and develop-
ing into oocysts 48 h after the blood meal [6, 7]. Over 
10–14  days, oocysts mature in the basal lamina of the 
midgut wall, forming sporozoites which are eventually 
released and migrate to the mosquito salivary glands, 
where they remain ready to initiate a new mammalian 
infection [4, 8, 9].
The complexity of the Plasmodium parasite’s 
life cycle constitutes one of the biggest hurdles in the 
fight against malaria. So far, the most successful strat-
egies to reduce the number of cases of malaria result 
from a combination of vector control strategies, and 
artemisinin combination therapies (ACT) that target 
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the symptomatic blood stage of infection [1]. How-
ever, the emergence of mosquito resistance to insecti-
cides and of parasite resistance to antimalarial drugs 
severely threaten the efficacy of such measures [1, 10]. 
Therefore, the identification of new compounds that 
have a broad spectrum of action, long half-life and 
strong inhibitory activity remains a priority in the fight 
against malaria.
Avermectins are a class of macrocyclic lactones with 
insecticidal and antiparasitic properties. They are the 
most effective and well-developed class of endecto-
cides, and are active against both endo- and ectopara-
sites [11]. Ivermectin, the best studied semi-synthetic 
derivate of avermectin, has been considered one of the 
most successful discoveries in the fight against infec-
tions caused by roundworm parasites [12]. Mass drug 
administration (MDA) of ivermectin in Africa and 
Latin America led to a reduction of onchocerciasis, as 
well as of lymphatic filariasis and scabies, which are 
also endemic in India and Southeast Asia [12–14]. The 
impact of ivermectin on insect vectors [12, 13], in par-
ticular its activity against Anopheles mosquitoes [15, 
16] prompted the investigation of its action against 
Plasmodium parasites, towards harnessing its poten-
tial use as an integrated tool for malaria control [17, 
18]. We have recently reported on ivermectin activity 
against Plasmodium liver stages in vivo [19]. However, 
discrepant results have emerged from several other 
studies aimed at assessing the impact of ivermec-
tin on the blood and mosquito stages of the Plasmo-
dium life-cycle [20–25]. Whereas results obtained by 
Nasveld et  al. [20] indicated that ivermectin displays 
very low activity against P. falciparum blood stages 
in vitro, Panchal et  al. [22] suggested that ivermec-
tin inhibits the parasite’s blood stage development by 
blocking nucleo-cytoplasmic shuttling of P. falciparum 
signal recognition particle (SRP) components. This is 
in agreement with a recent study that demonstrated 
an impairment of sexual and asexual stages of P. falci-
parum development in vitro [25]. On the other hand, 
ivermectin was reported to reduce oocyst prevalence 
and intensity in different mosquito species infected 
with P. falciparum [21], contrary to reports by Koby-
linski et  al. [23] and Pinilla et  al. [24], who did not 
observe a reduction on oocyst intensity, i.e. the num-
ber of oocysts per mosquito, but rather a decrease on 
oocyst prevalence (the proportion of mosquitoes har-
bouring oocysts), for P. vivax and P. falciparum.
The present study aimed to clarify the impact of 
ivermectin on P. berghei blood stages in vivo, as well as 
to assess the impact of ivermectin and other avermec-
tins on the parasite’s mosquito stages in vitro.
Methods
Experimental animals and P. berghei ANKA reference lines
Male BALB/cByJ mice (6–8  weeks-old) purchased from 
Charles River Laboratories Inc. (Lyon, France) were 
used. Two parasite lines were employed in the experi-
mental work, a transgenic parasite line termed PbC-
SGFP-Luc (RMgm-152),which expresses the fusion 
gene gfp-luc under the control of the csp promotor 
(PBANKA_0403200) integrated into the silent 230p gene 
locus (PBANKA_0306000) [26], and the transgenic para-
site line PbFluo-frmg (RMgm-164), which expresses GFP 
under control of the ‘male gametocyte-specific’ promoter 
of PB000791.03.0 (dynein heavy chain, putative) and RFP 
under the control of the ‘female gametocyte-specific’ 
promoter PB000504.02.0 (LCCL domain-containing pro-
tein CCP2). The rfp and gfp genes are integrated into the 
genome in the 230p locus (PBANKA_0306000) [27].
Ookinete production
Plasmodium berghei ANKA expressing green fluores-
cent protein (GFP) and luciferase under the control 
of the circumsporozoite protein (CSP) promoter (line 
784cl1, RMgm-152, PbCSPGFP-Luc) was maintained in 
Anopheles stephensi mosquitoes and BALB/cByJ mice. 
To maintain gametocyte infectivity, only up to six pas-
sages of parasites from infected to naïve mice were per-
formed. Ookinete in vitro production was performed 
as previously described [26]. Briefly, BALB/cByJ mice 
were treated with 0.1 ml phenylhydrazine (25  mg/ml) 3 
days prior to infection with  107 P. berghei-infected red 
blood cells (iRBC) obtained from a donor mouse. On 
the third day after infection, gametocytemia was moni-
tored by light microscopy for the presence of exflagel-
lating gametocytes in ookinete medium (1:4 dilution). 
Blood collected by heart puncture was pooled from 2 
mice and washed with RPMI at 37  °C, followed by cen-
trifugation at 1100×g for 10 min at 37 °C. After washing, 
5  μl of blood containing exflagellating gametocytes was 
mixed with medium supplemented for ookinete forma-
tion [RPMI1640 (Sigma-Aldrich, Saint Louis, USA), 25 
mM HEPES, 0.4 mM hypoxanthine, 100 mM xanthurenic 
acid (85570, Fluka, Saint Gallen, Switzerland), 10% FBS 
(pH 7.6)] in a final volume of 200  μl, and cultured in 
96-well plates for 24 h at 19 °C. Additionally, blood con-
taining exflagellating gametocytes was mixed with the 
ookinete medium in 1:20 ratio and cultured in T75 flasks 
for 22–24  h at 19  °C. Following incubation, ookinete 
enrichment was performed as previously described [26], 
with some modifications. Briefly, cultured blood was 
collected, and erythrocytes were lysed for 15 min on ice 
with 30 volumes of ice-cold 0.17 M ammonium chloride. 
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Lysed erythrocytes were removed by washing with RPMI, 
and ookinetes were purified by centrifugation on a 63% 
Nycodenz cushion at 650×g at 4  °C for 30 min. Follow-
ing centrifugation, the ookinete-containing interface was 
collected, washed in ice-cold RPMI and resuspended in 
0.5–1.0 ml of oocyst medium.
Oocyst cultures
Purified ookinetes were seeded with Drosophila mela-
nogaster S2 cells (Drosophila Genomics Resource Center, 
Bloomington, USA) in a 1:10 ratio  (104 ookinetes and  105 
S2 cells) in Schneider’s medium (S0146, Sigma-Aldrich) 
supplemented with 15% FBS, penicillin/streptomycin 
(50  U/ml, 50  µg/ml) and gentamicin (50  µg/ml) to pro-
mote oocyst development. Oocysts were co-cultured 
with D. melanogaster S2 cells in flat bottom 96-well 
plates (Corning, New York, USA) for up to 15 days at 
19 °C. One-quarter of the medium was changed 3 times 
per week (every 48 to 72 h), and  105 S2 cells were added 
once per week. In parallel, S2 cells were maintained at 
27  °C in Schneider’s medium (S0146, Sigma-Aldrich) 
supplemented with 10% FBS and penicillin/streptomycin 
(50 U/ml, 50 µg/ml).
Bioluminescence assay
A bioluminescence assay was used to assess the develop-
ment of the mosquito stages of PbCSGFP-Luc. In order 
to evaluate the effect of compounds on the develop-
ment of the parasite’s mosquito stages, samples were col-
lected at 3 different time points to determine the effect 
on ookinete and oocyst formation, and oocyst matura-
tion, as previously described [26]. The bioluminescence 
assay was performed using the Firefly Luciferase Assay 
Kit (Biotium, Hayward, USA) according to the manu-
facturer’s instructions, with some modifications. Briefly, 
the whole well contents were collected and spun down, 
washed with PBS, frozen in 50 µl of lysis buffer (1:5 ratio) 
and stored at − 20 °C until further use. Collected samples 
were lysed and 30  µl of the resulting supernatant were 
transferred into white 96-well plates. Fifty µl of D-lucif-
erin in Firefly luciferase assay buffer (1:50 ratio) were 
added to the samples and parasite load was determined 
by measuring luminescence intensity using a microplate 
reader (Tecan Infinite M200, Zurich, Switzerland).
Evaluation of the in vivo activity of ivermectin
In order to assess the in vivo activity of Iv, five BALB/
cByJ (Charles River) mice per experimental group were 
infected by intraperitoneal injection of  107 P. berghei 
Fluo-frmg-infected red blood cells. Parasitaemia and 
gametocyteamia were measured the following days by 
flow cytometry analysis of 4  µl of tail blood. Blood was 
collected in 200 µl of PBS and 100 µl stored at 4 °C, while 
the remaining was transferred to 100 µl of PBS contain-
ing 1.25 mM of red fluorescent nucleic acid stain Syto®61 
(Thermo Fisher Scientific, Waltham, USA) and incubated 
for 20 min at room temperature in the dark. The samples 
were analysed on a LSRFortessa X-20 flow cytometer 
(Becton, Dickinson and Co., New Jersey, USA). Female 
and male gametocytes were gated based on the analysis 
of GFP and Red Fluorescence Protein (RFP) fluorescence, 
and parasitemia was estimated based on the analysis of 
Syto®61 and forward scatter. The positive cell population 
was determined by comparison of infected blood samples 
with an uninfected blood sample. Results were then ana-
lysed with the  FlowJoTM Software (Version 10,  FlowJoTM 
Software, Ashland, USA). Exflagellation was also moni-
tored every day, until parasitemia reached 3% by micros-
copy analysis. To this end, 2.5  µl of tail blood were 
collected and mounted on a glass slide, and 8 min later 
the number of exflagellation events present in 4 inde-
pendent fields of vision at 40× were determined. When 
parasitemia reached up to 3%, either DMSO or ivermec-
tin were administered by oral gavage, at a concentration 
of 5 mg/kg, to five mice of each experimental group. Par-
asitemia, gametocytemia and exflagellation were moni-
tored for 3 days after treatment, following which the mice 
were euthanized, and the experiment was terminated.
Evaluation of the in vitro activity of avermectin compounds
The effect of eprinomectin, abamectin, ivermectin, mox-
idectin, doramectin and emamectin on the Plasmodium 
mosquito stages was evaluated as previously described 
[26]. The compounds were dissolved in dimethyl sul-
foxide (DMSO) and the amount of DMSO equivalent to 
that present in the highest compound concentration was 
used as a control. The effect of 10 µM of each compound 
was assessed on ookinetes, and on oocyst development 
and maturation. Briefly, after 1 h of incubation, the com-
pounds were added to 5  µl of infected blood cultures, 
and the bioluminescence intensity of the parasites on 
the ookinete cultures was assessed 24  h later. To assess 
the effect of the compounds on oocyst development and 
maturation, compounds were mixed with the mature 
ookinetes, and parasites collected after 3 days of culture 
or compounds were added to the oocyst culture after 
3 days of culture, and parasites collected 15 days later.
Compound concentration resulting in 50% inhibition 
 (IC50) for oocyst growth and maturation were estimated 
for eprinomectin, abamectin, ivermectin, moxidectin, 
doramectin and emamectin (assayed at 0.05, 0.5, 1, 5, 10, 
25 and 50 µM) by nonlinear regression analysis.
Evaluation of avermectin compounds’ in vitro cytotoxicity
Compounds were screened for their in vitro cyto-
toxicity against D. melanogaster S2 cells, using the 
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AlamarBlue® assay (Invitrogen, Carlsbad, USA). This 
assay allows to measure metabolic activity based on a 
fluoremetric/colorimetric indicator [28]. To assess the 
effect of the compounds on cell development, Dros-
ophila melanogaster S2 cells were seeded in a 1:10 ratio 
 (105 S2 cells) in Schneider’s medium (S0146, Sigma-
Aldrich) supplemented with 15% FBS, penicillin/strep-
tomycin (50  U/ml, 50  µg/ml) and gentamicin (50  µg/
ml). All the above-mentioned compounds were added 
to the S2 cell cultures to a final concentration of 10 µM 
and the amount of DMSO equivalent to that present 
in the highest compound concentration was used as a 
control. Cultures were maintained for 7 days and one-
quarter of the medium was changed 3 times per week 
every 48 to 72  h. Samples were collected every day 
by removing 120  µl of medium and adding 80  µl of 
AlamarBlue previously diluted in Schneider’s medium 
(1:10 dilution) to each well. The suspension was trans-
ferred to a 96 well flat bottom plate and incubated for 
one and a half hours at 37  °C. Fluorescence intensity 
was then measured using a microplate reader (Tecan 
Infinite M200) at 530 nm excitation wavelength/590 nm 
emission wavelength to determine cell viability.
Statistical analysis
Data on the assessment of the compounds’ effect in vitro 
were analysed using the Kruskal-Wallis test. Data on 
the compounds’ effect on parasitemia, gametocytemia 
and exflagellation in vivo were analysed employing non-
linear regression analysis. Results were considered sig-
nificant for P-values < 0.05. Nonlinear regression analysis 
was employed to fit the normalized results of the dose-
response curves for  IC50 determination. All statistical 
tests were performed by GraphPad Prism (version 6.00, 
GraphPad Software, La Jolla, USA).
Results
In vivo activity of ivermectin against P. berghei blood 
stages
A mouse model of infection was employed to evaluate the 
effect of ivermectin on P. berghei sexual and asexual blood 
stage forms in vivo, as described (Fig. 1a). Our results show 
no statistically significant differences between untreated 
controls and ivermectin-treated mice regarding overall 
parasitemia (F(1, 26) = 0.074, P = 0.78), percentage of the 
parasite’s male and female gametocytemia (F(1, 26) = 0.18, 
P = 0.67 and F(1, 26) = 0.079, P = 0.78, respectively), and 
exflagellation events (F(1, 26) = 0.33, P = 0.57) up to 5 days 
after infection (Fig. 1b–d). These data suggest that, at the 
tested dosage, ivermectin does not appear to significantly 
inhibit Plasmodium asexual and sexual forms in the blood.
In vitro activity of avermectins against P. berghei 
sporogonic development
We then sought to clarify whether the proposed trans-
mission-reducing activity of ivermectin would include a 
direct action of the drug on the parasite’s transmission 
stages in the mosquito or if it would result solely from 
its effect on the mosquito. Given the marked structural 
similarities between avermectins, the effect an additional 
5 compounds of this family, doramectin, moxidectin, 
abamectin, emamectin, and eprinomectin on the para-
site’s sporogonic stages was also evaluated, as described 
(Fig. 2a).
Our assessment of the compounds’ effect on the trans-
formation of gametes/zygote into ookinetes, showed that 
whereas emamectin inhibited parasite differentiation by 
approximately 47%, ivermectin and the remaining aver-
mectins had a very small and non-significant impact on 
the formation of ookinetes (Fig.  2b). The effect of aver-
mectins on oocyst formation and growth was subse-
quently assessed. At 10  µM, both these processes are 
inhibited by at least 50% by all compounds (Fig.  2c, d). 
Half-maximal inhibitory concentrations  (IC50) for oocyst 
formation by the compounds under evaluation were 
then determined and found to range from ~ 5.7  µM to 
~ 11.6 µM, with eprinomectin, doramectin and emamec-
tin displaying the greatest potency against this early stage 
of parasite sporogony (Table  1, Additional file  1: Figure 
S1a). Their  IC50 values for oocyst growth varied between 
~ 4.3 µM and ~ 9.3 µM (Table 1, Additional file 1: Figure 
S1b), with eprinomectin, doramectin and moxidectin 
standing out as the three compounds that most potently 
inhibited oocyst development (Table  1). Since oocysts 
are co-cultured in the presence of Drosophila S2 cells, we 
evaluated the latter’s viability for up to 7 days in the pres-
ence of each of the compounds under study (Additional 
file 1: Figure S2). Of note, these results indicate that ema-
mectin displays some cytotoxicity against S2 cells, which 
might suggest a moderate overestimation of this com-
pound’s activity against developing oocysts.
Discussion
In the present study, we aimed to assess the impact of 
ivermectin on the blood stages of P. berghei in  vivo, as 
well as the effect of several avermectins on the parasite’s 
mosquito stages in vitro. Our results show that ivermec-
tin is not active against Plasmodium asexual and sexual 
blood forms in a mouse model. However, both ivermec-
tin and other members of the avermectin family strongly 
inhibited parasite sporogony, at  IC50 values consistent 
with those reported for the antibiotic thiostrepton and 
the antimalarial pyronaridine, whose impact on sporo-
gony has been demonstrated [29].
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In light of their versatility as antiparasitic and insecti-
cidal compounds, avermectins and, particularly ivermec-
tin, have been considered as potential aids in the fight 
against malaria [16, 18, 19, 21–23]. Of note, the use of 
ivermectin in MDA to treat other neglected tropical dis-
eases in malaria-endemic regions has led to the investi-
gation of its potential to block malaria transmission [18, 
30, 31]. A recent study showed that a 3 weekly MDA of 
ivermectin in African villages reduced the incidence of 
uncomplicated malaria episodes among children, which 
the authors attributed to the drug’s mosquitocidal effect 
[18]. However, it should be noted that the results of this 
study have recently been questioned on the basis of the 
statistical methods employed [32].
Nevertheless, the issue of whether the impact of iver-
mectin stems solely from its impact on mosquitoes or, 
additionally, results from a combination of its insecticidal 
activity and of its ability to inhibit the parasite’s blood 
and mosquito stages remains unresolved. In fact, while 
the inhibitory effect of ivermectin against the liver stages 
of Plasmodium parasites has been demonstrated [19], the 
evaluation of its impact against the blood [20, 22, 25] and 
sporogonic [15, 23, 24] stages of the parasite’s life-cycle 
has yielded contradictory results [15, 20, 22–25].
In invertebrates, ivermectin interacts with the glu-
tamate-gated chloride channels in neuronal and neu-
romuscular tissues [33–35] and may also act on the 
γ-aminobutyric acid-gated chloride channels [36–38]. 
Fig. 1 Ivermectin activity against P. berghei asexual and sexual blood stages in the mammalian host. a Schematics of assessment of in vivo 
compound activity on parasitemia, gametocytemia and exflagellation of mice treated with ivermectin. b In vivo activity of ivermectin on parasitemia 
of mice treated by a single oral dosage of ivermectin. Results are a representation of Syto 61 positive events on flow cytometry analysis and are 
expressed as the mean of parasitemia values (percentage of infected red blood cells) ± standard deviation (SD). c In vivo activity of ivermectin on 
female and male gametocytemia of mice treated by a single oral dosage of ivermectin. Female gametocytemia is represented by a dashed line and 
male gametocytemia by a solid line. Female and male gametocytes were identified by flow cytometry analysis of  RFP+ or  GFP+ events, respectively. 
Results are expressed as the mean of gametocytemia values (percentage of gametocytes) ± SD. d In vivo activity of ivermectin on the number 
of exflagellation events per 40× microscopic field of mice treated by a single oral dosage of selected drug. Results are expressed as the mean of 
observed exflagellation events ± SD. Abbreviations: ns, non-significant
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However, neither of these molecular targets is pre-
sent in P. falciparum, which might explain the lack of 
ivermectin in vitro effect against P. falciparum blood 
stages [20]. Contradictorily, ivermectin was reported 
to lead to the arrest the development of P. falciparum 
blood stages by inhibiting the nuclear import of SRP 
polypeptides, thus arresting parasite growth [22]. The 
sporontocidal activity of ivermectin against P. vivax in 
An. darlingi led to a reduction of oocyst prevalence, 
but not of their intensity [24], similarly to what has 
been observed for P. falciparum in An. gambiae [16]. 
This contradicts previous studies suggesting that iver-
mectin reduces oocyst prevalence and intensity in An. 
dirus and An. minimus [21]. Although the mechanism 
of action of ivermectin against the sporogonic stages of 
Fig. 2 Activity of avermectins against Plasmodium mosquito stages in vitro. a Schematics of the progress of the parasite culturing process, 
highlighting the different schedules of compound treatment employed. b Assessment of compound effects on ookinete formation, expressed as 
the percentage of inhibition of P. berghei ookinete formation. c In vitro activity of selected compounds against oocyst formation. d In vitro activity 
of selected compounds on oocyst development. A total of 6 compounds were screened at a concentration of 10 μM: Iv; Do, Ep, Mo, Ab and Em. 
Bars correspond to RLU measurements represented as the percentage of RLU of the DMSO control. Results are expressed as the mean + SD. ****P < 
0.0001, ***P < 0.001, **P < 0.01. Abbreviations: Iv, ivermectin; Do, doramectin; Ep, eprinomectin; Mo, moxidectin; Ab, abamectin; Em, emamectin
Table 1 IC50 of avermectins against oocyst formation and 
maturation in vitro 
Notes: Compound concentration resulting in 50% inhibition (IC50) for oocyst 
growth and maturation were calculated for Ep, Do, Em, Ab, Mo, and Iv (assayed 
at 0.05, 0.5, 1, 5, 10, 25 and 50 µM). Results are expressed as the mean ± SD
Abbreviations: Ep, eprinomectin; Do, doramectin; Em, emamectin; Ab, 
abamectin; Mo, moxidectin; Iv, ivermectin
Compound Day0–Day3 (µM) Day3–Day15 (µM)
IC50 SD IC50 SD
Eprinomectin 5.70 2.31 4.59 2.26
Doramectin 7.08 1.91 4.32 1.76
Emamectin 7.31 2.45 7.36 1.50
Abamectin 8.77 4.38 7.93 4.14
Moxidectin 10.85 8.56 5.49 1.00
Ivermectin 11.58 0.44 9.32 1.64
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Plasmodium parasites remains to be elucidated, these 
observations suggest that the compound may act on the 
mosquito midgut physiology, preventing parasite estab-
lishment [23]. As such, the different results obtained 
experimentally in previous studies might result from 
differences in insect biology.
Our study sheds a new light on these controversial 
issues and helps clarify whether ivermectin exerts an 
impact on the blood and/or on the mosquito stages of 
Plasmodium parasites. Our in vivo investigation revealed 
that treatment of infected mice with 5 mg/kg of ivermec-
tin had no impact on parasitemia, indicating an absence 
of activity of this compound against the parasite’s asexual 
forms in the blood, in accordance with Nasveld et al. [20] 
for P. falciparum.
To further clarify whether a direct drug effect on 
Plasmodium mosquito stages contributes to transmis-
sion blocking, ivermectin and other avermectins were 
employed in a mosquito-free in vitro assay. Our results 
indicate that while these compounds exert little or no 
activity against ookinete formation, they efficiently 
inhibit the parasite’s sporogonic stages after fertiliza-
tion, most effectively targeting late stage oocysts. Further 
investigation on the mechanism of action of avermectins 
is required in order to fully clarify the exact targets of 
their activity against Plasmodium sporogony.
Conclusions
Our results suggest that the impact of ivermectin on 
Plasmodium transmission does not result from an inhibi-
tion of Plasmodium spp. transmissible forms in the mam-
malian host, and stems solely from its effect during the 
mosquito stage of infection. Our data show that the tran-
sition from gamete/zygote to ookinete is highly resistant 
to avermectins, and that the oocyst is the most vulner-
able stage of the parasite’s sporogonic cycle to treatment 
with avermectins. Collectively, these observations sup-
port the notion that, besides their mosquitocidal effect, 
avermectins may also directly target the parasite’s sporo-
gonic stages, which likely contributes to transmission-
blocking activity. Our results lend further support to the 
use of avermectins for MDA as a tool for malaria control 
in endemic regions, and suggest that the inclusion of 
members of this family of avermectin compounds besides 
ivermectin in these interventions should be considered.
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Additional file 1: Figure S1. Dose-response of avermectins against 
Plasmodium sporogonic stages. a Representative curves of avermectins 
effect resulting in 50% inhibition  (IC50) of oocyst formation. Curves are 
presented for Ep, Do, Em, Ab, Mo and Iv (assayed at 0.05, 0.5, 1, 5, 10, 25 
and 50 µM). Results are expressed as the mean ± standard deviation (SD). 
b Representative curves of avermectinʼs effect resulting in 50% inhibition 
 (IC50) of oocyst maturation. Curves are presented for Ep, Do, Em, Ab, Mo 
and Iv (assayed at 0.05, 0.5, 1, 5, 10, 25 and 50 µM). Results are expressed 
as the mean ± SD. Figure S2. Evaluation of avermectinʼs cytotoxicity 
on S2 cells. Determination of cell viability in a time course of 7 days by 
the AlamarBlue® assay. Results are normalized to the DMSO control and 
expressed as the mean ± SD. Abbreviations: DMSO, dimethyl sulfoxide; 
Ep, eprinomectin; Do, doramectin; Em, emamectin; Ab, abamectin; Mo, 
moxidectin; Iv, ivermectin.
Abbreviations
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